Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia

Fibrous dysplasia (FD) is a rare bone disorder caused by mutations of the GNAS gene, which are also identified in malignancies. We explored the potential relationship between breast cancer and fibrous dysplasia in two fibrous dysplasia cohorts from the Netherlands and the United States. Data on fibrous dysplasia and breast cancer diagnosis were retrieved from hospital records of 134 (Netherlands) and 121 (US) female patients. Results were validated with breast cancer data of 645 female fibrous dysplasia patients from the Dutch Pathology Registry (PALGA). Standardized morbidity ratios for breast cancer were estimated with data from Dutch and US general population registries. GNAS mutation was analyzed in 9 available breast cancer specimens. A combined total of 15 patients (6 polyostotic, 9 McCune‐Albright Syndrome) had breast cancer (87% thoracic localizations). In the Netherlands, a breast cancer incidence rate of 7.5% at median age of 46 years was validated in PALGA (6.5% at age 51 years). Breast cancer risk was 3.4‐fold increased (95% confidence interval [CI] 1.6–5.9) compared with the Dutch general population; OR 13.2‐fold (95% CI 6.2–22.8) in thoracic disease. In the US cohort, breast cancer incidence rate was 4.5% at a median age of 36 years. Breast cancer risk was 3.9‐fold increased (95% CI 1.2–8.2) compared with the general population; 5.7‐fold (95% CI 1.4–13.0) in thoracic disease. GNAS mutation was positive in 4 breast cancer specimens (44%). Risk of breast cancer is increased at a younger age, particularly in polyostotic FD, suggesting that screening for breast cancer should be considered in this particular group at a younger age than currently advocated by national guidelines. © 2017 American Society for Bone and Mineral Research.

[1]  M. Bastepe,et al.  GNAS Spectrum of Disorders , 2015, Current Osteoporosis Reports.

[2]  H. Ye,et al.  Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing , 2015, Human Genomics.

[3]  J. Lutterbaugh,et al.  GNAS Mutations Identify a Set of Right-Sided, RAS Mutant, Villous Colon Cancers , 2014, PloS one.

[4]  S. Aubert,et al.  Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions , 2013, Modern Pathology.

[5]  Eun Hee Lee,et al.  The diagnostic utility of the GNAS mutation in patients with fibrous dysplasia: meta-analysis of 168 sporadic cases. , 2012, Human pathology.

[6]  M. Collins,et al.  McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia , 2012, Orphanet Journal of Rare Diseases.

[7]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[8]  D. Jong,et al.  Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT , 2012, Oncogene.

[9]  E. Baracat,et al.  Evaluation of the insulin-like growth factors (IGF) IGF-I and IGF binding protein 3 in patients at high risk for breast cancer. , 2011, Fertility and sterility.

[10]  Andrew W Roddam,et al.  Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies , 2010, The Lancet. Oncology.

[11]  Charles P. Lin,et al.  Bone progenitor dysfunction induces myelodysplasia and secondary leukemia , 2010, Nature.

[12]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[13]  N. Kalfa,et al.  Activating Mutations of Gsα in Kidney Cancer , 2006 .

[14]  R. Lala,et al.  Genetics of McCune-Albright Syndrome , 2006, Journal of pediatric endocrinology & metabolism : JPEM.

[15]  L. Niskanen,et al.  A nationwide survey of mortality in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  R. Simmons,et al.  Ductal Carcinoma in Situ in a 27‐Year‐Old Woman with McCune‐Albright Syndrome , 2004, The breast journal.

[17]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[18]  M. Merino,et al.  Thyroid Carcinoma in the McCune-Albright Syndrome: Contributory Role of Activating Gsα Mutations , 2003 .

[19]  D. Edwards,et al.  Comparison of different antibodies for detection of progesterone receptor in breast cancer , 2002, Steroids.

[20]  S. Wientroub,et al.  Mutations of the GNAS1 Gene, Stromal Cell Dysfunction, and Osteomalacic Changes in Non–McCune–Albright Fibrous Dysplasia of Bone , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  T. Sawada,et al.  [Estrogen and progesterone receptors]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[22]  S. Toyoshima,et al.  Breast cancer in a patient with McCune-albright syndrome , 1998, Breast cancer.

[23]  J. Wereldsma,et al.  Wound infections after mastectomy or lumpectomy for breast cancer , 1997 .

[24]  K McPherson,et al.  ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. , 2000, BMJ.

[25]  T. Sano,et al.  Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction—primer‐introduced restriction analysis , 1993, Cancer.

[26]  M. Merino,et al.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. , 1991, The New England journal of medicine.

[27]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[28]  P. Chanson,et al.  Hepatobiliary and Pancreatic neoplasms in patients with McCune-Albright syndrome. , 2014, The Journal of clinical endocrinology and metabolism.

[29]  N. Kalfa,et al.  Activating mutations of Gsalpha in kidney cancer. , 2006, The Journal of urology.

[30]  M. Merino,et al.  Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. , 2003, The Journal of clinical endocrinology and metabolism.

[31]  S. Orme,et al.  Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. , 1998, The Journal of clinical endocrinology and metabolism.

[32]  G. Secreto,et al.  ENDOGENOUS HORMONES AND BREAST CANCER , 1998 .